Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday

Bicara Therapeutics (NASDAQ:BCAX) is anticipated to issue its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Bicara Therapeutics to announce earnings of ($0.8198) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:30 AM ET.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.21). On average, analysts expect Bicara Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Bicara Therapeutics Trading Up 3.6%

Shares of BCAX traded up $0.92 during midday trading on Tuesday, reaching $26.66. 192,820 shares of the company were exchanged, compared to its average volume of 590,991. Bicara Therapeutics has a 1-year low of $9.57 and a 1-year high of $30.99. The stock has a 50-day moving average price of $25.27 and a 200-day moving average price of $21.29. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -9.59 and a beta of -0.75.

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 28,214 shares of the stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total transaction of $817,641.72. Following the transaction, the chief operating officer directly owned 182,177 shares in the company, valued at $5,279,489.46. This represents a 13.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 28,000 shares of the stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total transaction of $807,800.00. Following the transaction, the chief financial officer owned 129,855 shares in the company, valued at $3,746,316.75. This trade represents a 17.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 88,450 shares of company stock valued at $2,366,675 over the last ninety days. Corporate insiders own 13.80% of the company’s stock.

Hedge Funds Weigh In On Bicara Therapeutics

Several large investors have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. lifted its stake in Bicara Therapeutics by 596.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after purchasing an additional 2,771,868 shares during the last quarter. Janus Henderson Group PLC bought a new stake in Bicara Therapeutics during the fourth quarter valued at $44,484,000. Vestal Point Capital LP increased its stake in Bicara Therapeutics by 80.6% during the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock valued at $46,450,000 after purchasing an additional 2,231,025 shares during the last quarter. Franklin Resources Inc. acquired a new stake in shares of Bicara Therapeutics during the fourth quarter worth $27,265,000. Finally, State Street Corp raised its holdings in shares of Bicara Therapeutics by 179.5% during the fourth quarter. State Street Corp now owns 1,649,537 shares of the company’s stock worth $27,762,000 after purchasing an additional 1,059,260 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Morgan Stanley upped their price target on Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. The Goldman Sachs Group boosted their target price on shares of Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Guggenheim started coverage on shares of Bicara Therapeutics in a research note on Monday, May 11th. They issued a “buy” rating and a $42.00 target price for the company. Wall Street Zen raised shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, May 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.27.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.